Ovarian Cancer

Cure Rate After Chemotherapy in Stage III Ovarian Cancer

By

Vicki Moore, PhD

Publish Date August 3, 2022

Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured.

Eligibility for First-Line PARP Inhibitor Maintenance in Advanced Ovarian Cancer

By

Lauren Dembeck, PhD

Publish Date July 12, 2022

Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, research suggests.

Effect of HIPEC With Cytoreductive Surgery on HRQOL in Patients With Advanced Ovarian Cancer

By

Jessica Nye, PhD

Publish Date July 11, 2022

A randomized study sought to determine the effect of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy on HRQOL for patients with advanced ovarian cancer.

Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer

By

Leah Lawrence

Publish Date June 22, 2022

There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.

Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer

By

Diana Ernst, RPh

Publish Date May 27, 2022

Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer